Ads
related to: curis inc stock
Search results
Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For Excitement
Simply Wall St. via Yahoo Finance· 4 months agoCuris, Inc. (NASDAQ:CRIS) shareholders would be excited to see that the share price has had a great...
Curis, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 9 months agoCuris, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call Transcript August 3, 2023 Curis, Inc. misses on...
Curis, Inc. (NASDAQ:CRIS) Shares Fly 75% But Investors Aren't Buying For Growth
Simply Wall St. via Yahoo Finance· 1 year agoCuris, Inc. (NASDAQ:CRIS) shareholders would be excited to see that the share price has had a great...
Investors in Curis (NASDAQ:CRIS) from five years ago are still down 87%, even after 15% gain this...
Simply Wall St. via Yahoo Finance· 2 years agoCuris, Inc. (NASDAQ:CRIS) shareholders should be happy to see the share price up 30% in the last...
What Kind Of Shareholders Hold The Majority In Curis, Inc.'s (NASDAQ:CRIS) Shares?
Simply Wall St. via Yahoo Finance· 2 years agoEvery investor in Curis, Inc. (NASDAQ:CRIS) should be aware of the most powerful shareholder groups....
Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 1 year agoCuris (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the...
Is Curis, Inc. (NASDAQ:CRIS) Trading At A 47% Discount?
Simply Wall St. via Yahoo Finance· 11 months agoKey Insights Using the 2 Stage Free Cash Flow to Equity, Curis fair value estimate is US$1.58...
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
Zacks via Yahoo Finance· 2 years agoThe FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of...
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Zacks via Yahoo Finance· 3 weeks agoCuris (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in...
Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain
Zacks via Yahoo Finance· 2 years agoThe FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating...
